Kigelia Africana

Kigelia africana contains naphthoquinones and steroidal saponins that exhibit antimicrobial and anti-inflammatory properties. These compounds, particularly kigelin and ferulic acid, help reduce skin inflammation and support wound healing. The iridoids present may also contribute to tissue repair. Evidence Level C suggests potential benefits based on preliminary research and traditional use, though more clinical trials are needed to fully understand the mechanism.

Limited research exists on Kigelia africana drug interactions. Due to its steroidal saponin content, theoretical interactions may occur with hormone therapies, hormonal contraceptives, or medications metabolised by the liver. Patients taking prescription medications should consult a healthcare provider before using Kigelia africana internally. No documented clinical interactions have been reported in current literature (Evidence Level D).

For adults, the typical internal dosage is 500mg of standardised extract taken twice daily. For topical use, apply Kigelia fruit extract cream to affected areas as directed on the product label. Dosage recommendations are based on traditional use and preliminary studies (Evidence Level C). Always follow manufacturer instructions and consult a qualified herbalist for personalised dosing guidance.

Kigelia africana is contraindicated during pregnancy and should not be used internally by pregnant women. The steroidal compounds present in the fruit may affect hormonal balance and uterine function. Breastfeeding women should also avoid internal use due to insufficient safety data. Topical preparations may be considered with medical supervision, but a patch test is recommended first to check for contact dermatitis (Evidence Level D).

Kigelia africana has been used traditionally across West and Central Africa for treating skin diseases, sores, and wounds. It is also employed for uterine fibroids, female reproductive disorders, and male prostate health support. The fruit is the primary part used medicinally. These applications are supported by ethnobotanical evidence and traditional knowledge (Evidence Level C), though clinical research remains limited.

Topical use of Kigelia africana may cause contact dermatitis in sensitive individuals, so a patch test is recommended before widespread application. Internal use can cause gastrointestinal disturbances including nausea and diarrhoea in some people. Discontinue use if adverse reactions occur. Those with known allergies to the Bignoniaceae plant family should avoid Kigelia products (Evidence Level C).